Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer-Clinical Trials Experience.
Izabela ChmielewskaKatarzyna StencelEwa KalinkaRodryg RamlauPaweł KrawczykPublished in: Cancers (2021)
Across all tumor types, we observe that the role of immunotherapy has increased rapidly. Due to a number of potential advantages, it is considered in neoadjuvant treatment of localized tumors. In neoadjuvant settings, immunotherapy addresses micrometastatic diseases at the moment of their formation. However, some issues concerning neoadjuvant and adjuvant immunotherapy still has to be covered. The choice of drug and use of monotherapy or combination regimens remains unclear. The timing of surgery and preoperative evaluation of neoadjuvant immunotherapy efficacy is challenging. Although there is currently limited confirmed clinical data to support the use of immune checkpoint blockade in the neoadjuvant and adjuvant settings, there are many studies exploring this strategy in NSCLC patients.
Keyphrases
- rectal cancer
- locally advanced
- lymph node
- early stage
- clinical trial
- squamous cell carcinoma
- small cell lung cancer
- radiation therapy
- minimally invasive
- end stage renal disease
- ejection fraction
- emergency department
- randomized controlled trial
- electronic health record
- machine learning
- open label
- patient reported outcomes
- big data
- decision making
- patient reported
- smoking cessation
- brain metastases